9. Claxton D, Suh S-P, Filaccio M, Ellerson D, Gaozza E, Andersson B, Brenner M, Reading C, Feinberg A, Moen R, Belmont 
J, Moore K, Talpaz M, Kantaijian H, and Deisseroth A: Molecular analysis of retroviral transduction in chronic myelogenous 
leukemia. Human Gene Therapy 2:317-321. 1991. 
10. Claxton D, Deisseroth A, Talpaz M, Reading C, Kantaijian H, Trujillo J, Stass S, Gooch G, and Spitzer G: Polyclonal 
hematopoiesis in interferon induced cytogenetic remissions of CML. Blood 79:997-1002, 1992. 
11. Etlcin M, Filaccio M, Ellerson D, Suh S-P, Claxton D, Gaozza E, Brenner M, Moen R, Belmont J, Moore KA, Mosely AM, 
Reading C, Khouri I, Talpaz M, Kantaijian H, and Deisseroth A: Use of cell-free supernatants of safety-modified viruses for 
transduction of cells from the marrow of chronic phase and blast crisis CML patients and from normal individuals. Human Gene 
Therapy 3:137-145. 1992. 
12. Moore K, Reading C, Deisseroth A, William D, and Belmont J: Stromal support allons efficient cell free retroviral vector 
transduction of human bone marrow long term culture initiating cells. Blood 79:1393-1399, 1992. 
13. Wedrychowski A, Henzel W, Huston L, Paslidis N, Ellerson D, McRae M, Seong D, Howard OMZ, and Deisseroth A: 
Identification of proteins binding to interferon-inducible transcriptional enhancers in hematopoietic cells. J Biol Chem 267:4533- 
4540, 1992. 
14. Upadhyaya G, Guba SC, Sih SA, Feinberg AP, Talpaz M, Kantaijian HM, Deisseroth AB, and Emerson SG: Interferon-alpha 
restores the deficient expression of the cytoadhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia 
progenitor cells. J Clin Invest 88:2131-2136. 1991. 
15. Johnson E, Henzel W, and Deisseroth A: A protein disulfide isomerase isolated from chronic myelogenous leukemia cells alters 
complex formation between nuclear proteins and regulatory regions of interferon-inducible genes. J Biol Chem 267:14412-14417, 
1992. 
16. Sims S, Cha Y, Romine M, Gao P-Q, Gottlieb K, and Deisseroth A: A novel interferon-inducible domain: Structural and 
functional analysis of the human IRF-1 gene promoter. In Press, Mol Cell Biol . 1993. 
17. del Giglio A, O'Brien S, Ford R, Saya H, Manning J, Keating M, Johnston D, Khetan R, El-Naggar A, and Deisseroth A: The 
prognostic value of proliferative cell nuclear antigen expression in chronic lymphoid leukemia. Blood 79:2717-2720, 1992. 
18. Zhang W, Drach J, Andreeff M, and Deisseroth A: Proliferation of hematopoietic cells is accompanied by suppressed expression 
of heat shock protein 70. Biochem Biophvs Res Comm 183:733-738, 1992. 
19. Cha Y, Sims S, Romine M, Kaufmann M, and Deisseroth A: Human interferon regulatory factor-1: Intron/exon organization. 
DNA and Cell Biology 11:605-611, 1992. 
20. Zhang W, Hittelman W, Van N, Andreeff M, and Deisseroth A: The phosphorylation of retinoblastoma gene product in human 
myeloid leukemia cells during the cell cycle. Biochem Biophvs Res Comm 184:212-216, 1992. 
21. Zhang W, Hu G, and Deisseroth A: Polymorphism at codon 72 of the p53 gene in human acute myelogenous leukemia. Gene 
117:271-275, 1992. 
22. Hu G, Zhang W, and Deisseroth A: P53 gene mutations in acute myelogenous leukemia. Br J Haematol 81:489-494, 1992. 
23. Kantaijian HM, Talpaz M, Kontoyiannis D, Gutterman J, Keating MJ, Estey EH, O’Brien S, Rios MB, Beran M, and Deisseroth 
A: Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and 
granulocyte-macrophage colony stimulating factor. J Clin Oncol 10: 398-405, 1992. 
24. Claxton DF, Reading CL, Nagarajan L, Tsujimoto Y, Andersson B, Estey E, Cork MA, Huh YO, Trujillo J and Deisseroth A: 
Correlation of CD2 expression with PML gene breakpoints in patients with acute promyelocytic leukemia. Blood 80:582-586, 
1992. 
25. Komblau S, Xu H-J, del Giglio A, Hu S-X, Zhang W, Smallwood L, Beran M, Estey E, Andreeff M, Trujillo J, Cork MA, 
Smith TL, Benedict WF, and Deisseroth A: Clinical implications of altered retinoblastoma protein expression in newly diagnosed 
and relapsed acute myelogenous leukemia. Cancer Res 52:4587-4590, 1992. 
26. Zhang W, Hu G, Estey E, Hester J, and Deisseroth A: Altered conformation of the p53 protein in myeloid leukemia cells and 
mitogen-stimulated normal blood Cells. Oncogene 7:1645-1647, 1992. 
27. Estey E, Thall PF, Kantaijian H, O’Brien S, Koller CA, Beran M, Gutterman J, Deisseroth A, and Keating M: Treatment of 
newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during 
continuous-infusion high-dose ara-C+Daunorubicin: Comparison to patients treated without GM-CSF. Blood 79:2246-2255, 1992. 
28. Estrov Z, Park CH, Reading CL, Estey EH, Talpaz M, Kurzrock R, Deisseroth AB, and Gutterman JU: The effect of 
granulocyte-macrophage colony-stimulating factor on undifferentiated and mature acute myelogenous leukemia blast progenitors. 
Exp Hematol 20:886-890, 1992. 
29. Seong DC, Gottlieb K, Suh S-P, Sims S, Talpaz M, Kantaijian H, and Deisseroth A: Identification of a complex formed between 
nuclear proteins and the transcriptional enhancer of interferon-inducible genes that is present in the peripheral blood myeloid cells 
of CML but not normal individuals. J Interferon Res 12:323-327, 1992. 
Recombinant DNA Research, Volume 17 
[681] 
